gefitinib has been researched along with pf 00299804 in 38 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (pf 00299804) | Trials (pf 00299804) | Recent Studies (post-2010) (pf 00299804) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 180 | 41 | 172 |
| Protein | Taxonomy | gefitinib (IC50) | pf 00299804 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.037 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0392 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.094 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.11 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.0006 | |
| Mitogen-activated protein kinase kinase kinase 8 | Homo sapiens (human) | 3.57 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 3.57 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.0494 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (5.26) | 29.6817 |
| 2010's | 22 (57.89) | 24.3611 |
| 2020's | 14 (36.84) | 2.80 |
| Authors | Studies |
|---|---|
| Anderton, MJ; Ashton, S; Bethel, PA; Box, M; Butterworth, S; Chorley, CG; Chuaqui, C; Colclough, N; Cross, DA; Dakin, LA; Debreczeni, JÉ; Eberlein, C; Finlay, MR; Grist, M; Hill, GB; Klinowska, TC; Lane, C; Martin, S; Orme, JP; Smith, P; Wang, F; Ward, RA; Waring, MJ | 1 |
| Althaus, IW; Black, SL; Blaser, A; Bridges, A; Denny, WA; Ellis, PA; Ellis, T; Fakhoury, S; Gonzales, AJ; Harvey, PJ; Hook, K; Lee, H; McCarthy, FO; Palmer, BD; Reed, JE; Rivault, F; Schlosser, K; Sexton, K; Smaill, JB; Spicer, JA; Tecle, H; Thompson, AM; Trachet, E; Winters, RT; Zhu, T | 1 |
| Abouzid, KAM; Lasheen, DS; Milik, SN; Serya, RAT | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q | 1 |
| Das, D; Hong, J | 1 |
| Asquith, CRM; Drewry, DH; East, MP; Havener, TM; Johnson, GL; Laitinen, T; Morris, DC; Naegeli, KM; Wells, CI; Zuercher, WJ | 1 |
| Abd El-Karim, SS; Ahmed, NS; Anwar, MM; El-Hallouty, SM; Srour, AM | 1 |
| An, B; Chen, C; Fan, R; Li, J; Li, X; Song, X; Wei, S; Zhang, Q; Zou, Y | 1 |
| Chen, XB; Wang, S; Wang, SQ; Yu, B; Yuan, XH; Zhao, W | 1 |
| Aziz, MW; Elgendy, AA; Kamal, AM; Mohamed, KO | 1 |
| Althaus, IW; Bradner, JE; Engelman, JA; Gale, CM; Gandhi, L; Gonzales, AJ; Heymach, JV; Jänne, PA; Lifshits, E; Meyerson, M; Naumov, GN; Nelson, JM; Shapiro, GI; Shimamura, T; Vincent, PW; Wong, KK; Zejnullahu, K; Zhao, F | 1 |
| Costa, DB; Kobayashi, S; Nguyen, KS | 1 |
| Brown, A; Capelletti, M; Christensen, JG; Engelman, JA; Ercan, D; Jänne, PA; Kwiatkowski, DJ; Lee, C; Lifshits, E; Rogers, A; Xiao, Y; Yonesaka, K; Zejnullahu, K | 1 |
| Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N | 1 |
| Brodsky, O; Feng, J; Ferre, R; Gajiwala, KS; Kath, JC; Ryan, K; Stewart, A; Weinrich, S | 1 |
| Ahn, MJ; Campbell, AK; Cho, BC; Gernhardt, D; Giri, N; Heo, DS; Kim, DW; Lee, SY; Letrent, SP; O'Connell, J; Park, K; Taylor, I; Zhang, H | 1 |
| Bowen, JM; Gibson, RJ; Van Sebille, YZ; Wardill, HR | 1 |
| Chen, G; Huang, X; Huang, Y; Kang, S; Miao, S; Wu, M; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H | 1 |
| Cheng, Y; Corral, J; Lee, KH; Linke, R; Migliorino, MR; Mok, TS; Nadanaciva, S; Nakagawa, K; Niho, S; Pluzanski, A; Rosell, R; Sandin, R; Sbar, EI; Tsuji, F; Wang, T; White, JL; Wu, YL; Zhou, X | 1 |
| Ahn, HJ; Bhatt, L; Kim, YH; Lee, WK; Nam, HW; Yang, Z | 1 |
| Gainor, JF; Piotrowska, Z | 1 |
| Cheng, Y; Corral, J; Lee, KH; Lee, M; Linke, R; Migliorino, MR; Mok, TS; Nakagawa, K; Niho, S; Pluzanski, A; Rosell, R; Sbar, EI; Wang, T; White, JL; Wu, YL; Zhou, X | 1 |
| Li, XF; Liu, GF; Miao, YY; Yu, SN; Zhang, SH | 1 |
| Ding, JY; Gao, J; Jiang, JH; Jin, C; Li, HR | 1 |
| Batra, U; Lau, SCM; Loong, HH; Mok, TSK | 1 |
| Sun, H; Wu, YL | 1 |
| Fujita, Y; Isozaki, M; Kaneda, H; Kato, T; Nakagawa, K; Niho, S; Nishio, M; Nogami, N; Takahashi, T; Tsuji, F; Wada, S; Wilner, K; Yamamoto, N; Yoshida, M | 1 |
| Ariyasu, R; Fujita, N; Katayama, R; Kitazono, S; Nishio, M; Tadokoro, K; Uchibori, K; Yamaguchi, T; Yanagitani, N | 1 |
| Mohty, R; Tfayli, A | 1 |
| Cheng, Y; Corral, J; Lee, KH; Linke, R; Meyers, O; Migliorino, MR; Mok, TS; Nakagawa, K; Niho, S; Paty, J; Płużański, A; Reisman, A; Sandin, R; Wu, YL; Zhou, X | 1 |
| Eisenstein, M | 1 |
| Chawla, A; Cheng, Y; Corral, J; Lee, KH; Migliorino, MR; Mok, TS; Nakagawa, K; Niho, S; Noonan, K; Pastel, M; Pluzanski, A; Rosell, R; Tang, Y; Wilner, KD; Wu, YL; Zhou, X | 1 |
| Gupta, A; Momi, G; Vaid, AK | 1 |
| Chai, J; Cui, JW; Li, LY; Li, WQ | 1 |
| Fujita, A; Hatsuyama, T; Inotsume, N; Mukai, Y; Sato, H; Toda, T; Wakamoto, A; Yoshida, T | 1 |
| Li, M; Mok, K; Mok, T | 1 |
12 review(s) available for gefitinib and pf 00299804
| Article | Year |
|---|---|
How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Gene Amplification; Humans; Models, Molecular; Neoplasms; Point Mutation; Protein Domains; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2017 |
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines | 2019 |
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Molecular Structure; Neoplasms; Pyrimidines; United States; United States Food and Drug Administration | 2021 |
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Quinazolinones | 2009 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles | 2012 |
Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Network Meta-Analysis; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic | 2019 |
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Class I Phosphatidylinositol 3-Kinases; Disease Progression; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Quinazolinones; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; Signal Transduction | 2019 |
Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolinones | 2019 |
Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Lung Neoplasms; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolinones; Receptor, ErbB-2; Receptor, ErbB-4 | 2019 |
Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review).
Topics: Acrylamides; Administration, Oral; Afatinib; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolinones; Randomized Controlled Trials as Topic | 2021 |
7 trial(s) available for gefitinib and pf 00299804
| Article | Year |
|---|---|
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins; Republic of Korea; Treatment Outcome | 2014 |
Dacomitinib Beats Gefitinib for EGFR
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2017 |
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Prognosis; Quinazolines; Quinazolinones; Survival Analysis; Treatment Outcome | 2017 |
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolinones; Survival Rate | 2018 |
Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolinones; Treatment Outcome | 2020 |
The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gain of Function Mutation; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Patient Reported Outcome Measures; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Quinazolinones; Response Evaluation Criteria in Solid Tumors | 2021 |
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolinones; Survival Analysis | 2021 |
19 other study(ies) available for gefitinib and pf 00299804
| Article | Year |
|---|---|
Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
Topics: ErbB Receptors; Models, Molecular; Mutation; Structure-Activity Relationship | 2013 |
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Dogs; ErbB Receptors; Heterografts; Humans; Injections, Intravenous; Macaca fascicularis; Male; Mice, Nude; Morpholines; Neoplasm Transplantation; Phosphorylation; Pyridines; Pyrimidines; Quinazolines; Quinazolinones; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship | 2016 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chordoma; Drug Design; ErbB Receptors; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines | 2019 |
Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; MCF-7 Cells; Molecular Docking Simulation; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Thiazoles | 2020 |
Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; ErbB Receptors; Humans; Male; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2021 |
Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Quinazolinones; Structure-Activity Relationship | 2021 |
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Cloning, Molecular; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Oncogene Proteins v-erbB; Quinazolines; Quinazolinones | 2007 |
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2010 |
Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation, Missense; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Protein Stability; Protein Structure, Secondary; Quinazolines; Quinazolinones; Sf9 Cells; Spodoptera | 2013 |
Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2016 |
Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells.
Topics: Afatinib; Aminoquinolines; Aniline Compounds; Animals; Cell Line; Gefitinib; Humans; Mice, Inbred BALB C; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Quinolines; Receptor, ErbB-2; Toxoplasma; Tyrphostins | 2017 |
ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolinones | 2018 |
Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.
Topics: Aged; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gain of Function Mutation; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolinones; Retrospective Studies; Sequence Deletion | 2020 |
EGFR tyrosine kinase inhibitors in non-small cell lung cancer: treatment paradigm, current evidence, and challenges.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolinones | 2021 |
New lung-cancer drugs extend survival times.
Topics: Acrylamides; Afatinib; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Gefitinib; Hope; Humans; Lactams; Lung; Lung Neoplasms; Piperidines; Programmed Cell Death 1 Receptor; Pyrazoles; Quinazolinones; Survival Analysis | 2020 |
Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
Topics: Acrylamides; Angiogenesis Inhibitors; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; China; Clinical Trials as Topic; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Markov Chains; Mutation; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolinones | 2021 |
An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carbazoles; Chromatography, Liquid; Crizotinib; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Quinazolinones; Sulfones; Tandem Mass Spectrometry | 2021 |
A Detouring Experience Not Recommended: Lessons Learned from PF00299804.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolinones; Receptor, ErbB-2 | 2022 |